Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Linda Hoang is active.

Publication


Featured researches published by Linda Hoang.


Emerging Infectious Diseases | 2016

Decline in Decreased Cephalosporin Susceptibility and Increase in Azithromycin Resistance in Neisseria gonorrhoeae, Canada

Irene Martin; P. Sawatzky; G. Liu; Allen; Brigitte Lefebvre; Linda Hoang; S. Drews; Greg Horsman; John L. Wylie; David Haldane; Richard Garceau; Sam Ratnam; Tom Wong; Chris P. Archibald; Michael R. Mulvey

Antimicrobial resistance profiles were determined for Neisseria gonorrhoeae strains isolated in Canada during 2010–2014. The proportion of isolates with decreased susceptibility to cephalosporins declined significantly between 2011 and 2014, whereas azithromycin resistance increased significantly during that period. Continued surveillance of antimicrobial drug susceptibilities is imperative to inform treatment guidelines.


Journal of Clinical Microbiology | 2015

Molecular Assay for Detection of Genetic Markers Associated with Decreased Susceptibility to Cephalosporins in Neisseria gonorrhoeae

Shelley W. Peterson; Irene Martin; Walter Demczuk; Amrita Bharat; Linda Hoang; John L. Wylie; Vanessa Allen; Brigitte Lefebvre; Greg Tyrrell; Greg Horsman; David Haldane; Richard Garceau; Tom Wong; Michael R. Mulvey

ABSTRACT The incidence of antimicrobial-resistant Neisseria gonorrhoeae continues to rise in Canada; however, antimicrobial resistance data are lacking for approximately 70% of gonorrhea infections that are diagnosed directly from clinical specimens by nucleic acid amplification tests (NAATs). We developed a molecular assay for surveillance use to detect mutations in genes associated with decreased susceptibility to cephalosporins that can be applied to both culture isolates and clinical samples. Real-time PCR assays were developed to detect single nucleotide polymorphisms (SNPs) in ponA, mtrR, penA, porB, and one N. gonorrhoeae-specific marker (porA). We tested the real-time PCR assay with 252 gonococcal isolates, 50 nongonococcal isolates, 24 N. gonorrhoeae-negative NAAT specimens, and 34 N. gonorrhoeae-positive NAAT specimens. Twenty-four of the N. gonorrhoeae-positive NAAT specimens had matched culture isolates. Assay results were confirmed by comparison with whole-genome sequencing data. For 252 N. gonorrhoeae strains, the agreement between the DNA sequence and real-time PCR was 100% for porA, ponA, and penA, 99.6% for mtrR, and 95.2% for porB. The presence of ≥2 SNPs correlated with decreased susceptibility to ceftriaxone (sensitivities of >98%) and cefixime (sensitivities of >96%). Of 24 NAAT specimens with matched cultures, the agreement between the DNA sequence and real-time PCR was 100% for porB, 95.8% for ponA and mtrR, and 91.7% for penA. We demonstrated the utility of a real-time PCR assay for sensitive detection of known markers for the decreased susceptibility to cephalosporins in N. gonorrhoeae. Preliminary results with clinical NAAT specimens were also promising, as they correlated well with bacterial culture results.


Journal of Clinical Microbiology | 2015

Molecular Assay for Detection of Ciprofloxacin Resistance in Neisseria gonorrhoeae Isolates from Cultures and Clinical Nucleic Acid Amplification Test Specimens

Shelley W. Peterson; Irene Martin; Walter Demczuk; Amrita Bharat; Linda Hoang; John L. Wylie; Vanessa Allen; Brigitte Lefebvre; Greg Tyrrell; Greg Horsman; David Haldane; Richard Garceau; Tom Wong; Michael R. Mulvey

ABSTRACT We developed a real-time PCR assay to detect single nucleotide polymorphisms associated with ciprofloxacin resistance in specimens submitted for nucleic acid amplification testing (NAAT). All three single nucleotide polymorphism (SNP) targets produced high sensitivity and specificity values. The presence of ≥2 SNPs was sufficient to predict ciprofloxacin resistance in an organism.


Canadian Journal of Infectious Diseases & Medical Microbiology | 2016

Characterization of Clostridium difficile Strains in British Columbia, Canada: A Shift from NAP1 Majority (2008) to Novel Strain Types (2013) in One Region

Agatha N. Jassem; Natalie Prystajecky; Fawziah Marra; Pamela Kibsey; Kennard Tan; Patricia Umlandt; Loretta Janz; Sylvie Champagne; Bruce Gamage; George R. Golding; Michael R. Mulvey; Bonnie Henry; Linda Hoang

Background. Clostridium difficile is a major cause of gastrointestinal illness. Epidemic NAP1 strains contain toxins A and B, a deletion in repressor tcdC, and a binary toxin. Objectives. To determine the molecular epidemiology of C. difficile in British Columbia and compare between two time points in one region. Methods. C. difficile isolates from hospital and community laboratories (2008) and one Island Health hospital laboratory (2013) were characterized by pulsed-field gel electrophoresis, PCR-ribotyping, toxin possession, tcdC genotype, and antimicrobial susceptibility. Results. In 2008, 42.7% of isolates had NAP1 designation. Hospital-collected isolates were associated with older patients and more NAP1 types. Unlike other isolates, most NAP1 isolates possessed binary toxin and a 19 bp loss in tcdC. All isolates were susceptible to metronidazole and vancomycin. A 2013 follow-up revealed a 28.9% decrease in NAP1 isolates and 20.0% increase in isolates without NAP designation in one region. Then, community-associated cases were seen in younger patients, while NAP types were evenly distributed. Isolates without NAP designation did not cluster with a PFGE pattern or ribotype. Conclusions. Evaluation of C. difficile infections within British Columbia revealed demographic associations, epidemiological shifts, and characteristics of strain types. Continuous surveillance of C. difficile will enable detection of emerging strains.


Antimicrobial Agents and Chemotherapy | 2017

Enterobacter cloacae Complex Isolates Harboring blaNMC-A or blaIMI-Type Class A Carbapenemase Genes on Novel Chromosomal Integrative Elements and Plasmids

David Boyd; Laura Mataseje; Ross J. Davidson; Johannes A. Delport; Jeffrey D. Fuller; Linda Hoang; Brigitte Lefebvre; Paul N. Levett; Diane Roscoe; Barbara M. Willey; Michael R. Mulvey

ABSTRACT Carbapenem-resistant Enterobacter cloacae complex isolates submitted to a reference laboratory from 2010 to 2015 were screened by PCR for seven common carbapenemase gene groups, namely, KPC, NDM, OXA-48, VIM, IMP, GES, and NMC-A/IMI. Nineteen of the submitted isolates (1.7%) were found to harbor Ambler class A blaNMC-A or blaIMI-type carbapenemases. All 19 isolates were resistant to at least one carbapenem but susceptible to aminoglycosides, trimethoprim-sulfamethoxazole, tigecycline, and ciprofloxacin. Most isolates (17/19) gave positive results with the Carba-NP test for phenotypic carbapenemase detection. Isolates were genetically diverse by pulsed-field gel electrophoresis macrorestriction analysis, multilocus sequence typing, and hsp60 gene analysis. The genes were found in various Enterobacter cloacae complex species; however, blaNMC-A was highly associated with Enterobacter ludwigii. Whole-genome sequencing and bioinformatics analysis revealed that all NMC-A (n = 10), IMI-1 (n = 5), and IMI-9 (n = 2) producers harbored the carbapenemase gene on EludIMEX-1-like integrative mobile elements (EcloIMEXs) located in the identical chromosomal locus. Two novel genes, blaIMI-5 and blaIMI-6, were harbored on different IncFII-type plasmids. Enterobacter cloacae complex isolates harboring blaNMC-A/IMI-type carbapenemases are relatively rare in Canada. Though mostly found integrated into the chromosome, some variants are located on plasmids that may enhance their mobility potential.


Journal of Antimicrobial Chemotherapy | 2018

Characterization of OXA-48-like carbapenemase producers in Canada, 2011–14

Laura Mataseje; David Boyd; Jeffrey D. Fuller; David Haldane; Linda Hoang; Brigitte Lefebvre; Roberto G. Melano; Paul Van Caeseele; Michael R. Mulvey

ObjectivesnSince the first identification of the OXA-48 carbapenemase in 2001, Enterobacteriaceae harbouring OXA-48-like enzymes have been reported globally. Here, we applied WGS to characterize the molecular epidemiology of these bacterial isolates.nnnMethodsnEnterobacteriaceae non-susceptible to carbapenems isolated from patients between 2011 and 2014 were voluntarily submitted to the Canadian National Microbiology Laboratory where they were screened for carbapenemase genes. WGS was conducted on OXA-48-like producers using the Illumina MiSeq platform. WGS data were used for single nucleotide variant (SNV) analysis, MLST analysis, detection of resistance genes and partial plasmid characterization. Susceptibilities were determined using Vitek2 and Etest. Patient data provided from sites were reviewed.nnnResultsnSixty-seven non-duplicated cases were identified among Escherichia coli (nu2009=u200921) and Klebsiella pneumoniae (nu2009=u200946). Recent international travel was observed in 40.4% of cases. OXA-181 (52.2%) and OXA-48 (31.3%) were the most common variants, one E. coli OXA-48 producer was found to harbour the acquired colistin resistance gene mcr-1. The dominant STs were ST38 and ST410 in E. coli and ST14 in K. pneumoniae. Three common plasmid types were observed among isolates: IncL/M associated with OXA-48 producers, and ColKP3 and IncX3 associated with OXA-181/232 producers.nnnConclusionsnEnterobacteriaceae with OXA-48-like carbapenemases are emerging in Canada. This study highlights the complexity of OXA-48-types identified in Canada owing to travel and the successful clones and plasmids harbouring the OXA-48-like enzyme.


Open Forum Infectious Diseases | 2018

Canada-Wide Epidemic of emm74 Group A Streptococcus Invasive Disease

Sarah Teatero; Allison McGeer; Gregory J. Tyrrell; Linda Hoang; Hanan Smadi; Marc-Christian Domingo; Paul N. Levett; Michael Finkelstein; Ken Dewar; Agron Plevneshi; Taryn B. T. Athey; Jonathan B. Gubbay; Michael R. Mulvey; Irene Martin; Walter Demczuk; Nahuel Fittipaldi

Abstract Background The number of invasive group A Streptococcus (iGAS) infections due to hitherto extremely rare type emm74 strains has increased in several Canadian provinces since late 2015. We hypothesized that the cases recorded in the different provinces are linked and caused by strains of an emm74 clone that recently emerged and expanded explosively. Methods We analyzed both active and passive surveillance data for iGAS infections and used whole-genome sequencing to investigate the phylogenetic relationships of the emm74 strains responsible for these invasive infections country-wide. Results Genome analysis showed that highly clonal emm74 strains, genetically different from emm74 organisms previously circulating in Canada, were responsible for a country-wide epidemic of >160 invasive disease cases. The emerging clone belonged to multilocus sequence typing ST120. The analysis also revealed dissemination patterns of emm74 subclonal lineages across Canadian provinces. Clinical data analysis indicated that the emm74 epidemic disproportionally affected middle-aged or older male individuals. Homelessness, alcohol abuse, and intravenous drug usage were significantly associated with invasive emm74 infections. Conclusions In a period of 20 months, an emm74 GAS clone emerged and rapidly spread across several Canadian provinces located more than 4500 km apart, causing invasive infections primarily among disadvantaged persons.


Canadian Journal of Infectious Diseases & Medical Microbiology | 2016

Genomic Analysis of a Serotype 5 Streptococcus pneumoniae Outbreak in British Columbia, Canada, 2005-2009.

Ruth R. Miller; Morgan G. I. Langille; Vincent Montoya; Anamaria Crisan; Aleksandra Stefanovic; Irene Martin; Linda Hoang; David M. Patrick; Marc Romney; Gregory J. Tyrrell; Steven J.M. Jones; Fiona S. L. Brinkman; Patrick Tang

Background. Streptococcus pneumoniae can cause a wide spectrum of disease, including invasive pneumococcal disease (IPD). From 2005 to 2009 an outbreak of IPD occurred in Western Canada, caused by a S. pneumoniae strain with multilocus sequence type (MLST) 289 and serotype 5. We sought to investigate the incidence of IPD due to this S. pneumoniae strain and to characterize the outbreak in British Columbia using whole-genome sequencing. Methods. IPD was defined according to Public Health Agency of Canada guidelines. Two isolates representing the beginning and end of the outbreak were whole-genome sequenced. The sequences were analyzed for single nucleotide variants (SNVs) and putative genomic islands. Results. The peak of the outbreak in British Columbia was in 2006, when 57% of invasive S. pneumoniae isolates were serotype 5. Comparison of two whole-genome sequenced strains showed only 10 SNVs between them. A 15.5u2009kb genomic island was identified in outbreak strains, allowing the design of a PCR assay to track the spread of the outbreak strain. Discussion. We show that the serotype 5 MLST 289 strain contains a distinguishing genomic island, which remained genetically consistent over time. Whole-genome sequencing holds great promise for real-time characterization of outbreaks in the future and may allow responses tailored to characteristics identified in the genome.


Canada Communicable Disease Report | 2017

Increase in Neisseria meningitidis serogroup W invasive disease in Canada: 2009–2016

Rsw Tsang; Linda Hoang; Greg Tyrrell; Gregory Horsman; P Van Caeseele; Frances Jamieson; Brigitte Lefebvre; David Haldane; Rr Gad; Gregory German; George Zahariadis


Relevé des maladies transmissibles au Canada | 2017

Augmentation des infections invasives à Neisseria meningitidis de sérogroupe W au Canada de 2009 à 2016

Rsw Tsang; Linda Hoang; Greg Tyrrell; Gregory Horsman; P Van Caeseele; Frances Jamieson; Brigitte Lefebvre; David Haldane; Rr Gad; Gregory German; George Zahariadis

Collaboration


Dive into the Linda Hoang's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Michael R. Mulvey

Public Health Agency of Canada

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Irene Martin

Public Health Agency of Canada

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Amrita Bharat

Public Health Agency of Canada

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Tom Wong

Public Health Agency of Canada

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Walter Demczuk

Public Health Agency of Canada

View shared research outputs
Researchain Logo
Decentralizing Knowledge